Feedback Share Price (FDBK)

2.18 -0.05 (-2.25%) delayed: 9:34AM BST
Bid price 2.05 Open price 2.27
Ask price 2.30 Prev close 2.18
High price 2.30 Spread 10.87%
Low price 2.08 Volume 2,320,252

Register now for FREE live Feedback share prices, Feedback stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Feedback Level 2 Data, indepth research tools and investor commentary for Feedback (FDBK) and other London Stock Exchange equities.

Feedback Share Price Chart

Advanced Charts >>

Register now for FREE Feedback share price charts

Feedback Share Price Information

Name Feedback Epic FDBK
Sector Electronic & Electrical Equipment ISIN GB0003340550
Activites Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD, the Company's patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world's leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. Index n/a

Feedback Key Numbers

Latest Share Price (p) 2.18 Net Gearing (%) -41.77
Market Capitalisation (£m) 6.28 Gross Gearing (%) 36.28
Shares in issue (m) 281.62 Debt Ratio 0.70
P/E Ratio -20.27 Debt-to-Equity Ratio 0.01
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.57
Dividend Yield (%) 0.00 Price to book value 11.02
Dividend cover (x) 0.00 ROCE (%) -52.63
Earning per share (p) -0.11 EPS Growth (%) -22.22
52 week high / low 3.58 / 1.22 DPS Growth (%) n/a

Feedback Director Deals

Dec.Date Type Director Pos No. of Shares
17/08/2018 SELL Mike Hayball NED 650,000
01/08/2018 SELL Mike Hayball NED 500,000
29/06/2018 BUY Simon Sturge NED 1,000,000
01/05/2018 BUY Simon Sturge NED 500,000
24/11/2016 TOUT Tom Charlton RES 5,000,000

More Feedback Director Deals >>

Feedback Company News

15:50 17/08/2018

Director Deals - Feedback PLC (FDBK)

Mike Hayball, Non Executive Director, sold 650,000 shares in the company on the 16th August 2018 at a price of 2.12p. The Director now holds 4,520,600 shares. NOTE: Average price over three transactions. Story provided by StockMarketWire.com Director deals data provided by...

14:02 17/08/2018

Director/PDMR Shareholding

RNS Number : 1943Y Feedback PLC 17 August 2018   17 August 2018 Feedback plc ( "Feedback" or the "Company")   Director/PDMR Shareholding Feedback plc, the specialist medical imaging technology company, announces that Mike Hayball, a PDMR of the Company, on...

09:26 15/08/2018

Feedback receives first order from GE Healthcare

Medical imaging company Feedback said Wednesday it had received its first order from GE Healthcare for the company's image texture analysis technology. The order for TexRAD, the company's image texture analysis technology, followed the distribution agreement announced on 25 April 2018, granting...

More Feedback Company News >>

Register now for FREE Feedback company news

Feedback Share Price Discussions

more than 1 year ago

Stakebuilding (FDBK)

Mr A. Malik is building a stake, now over 6.25%. A position on the Board or a takeover perhaps? FDBK is suffering under the pension fund deficit contingency, but with stock markets rising, the fund position may be improving. Sciences in the post secondary school seeing improvement and extra...

more than 1 year ago

Feedback still on it's way to a ten bagger (FDBK)

Anyone who occasionally reads posts from the darkside will know I bought these a while back when they were in single digit prices - now 21/23.5p. They have been immune from the markets general trials and tribulations and the price hasnt moved since early on this year. A big cross has just been...

Register now for FREE Feedback share price discussions